Helix BioPharma Corp.

HBP

CA4229101098

Biotechnology & Medical Research

Market Closed - Toronto S.E. Other stock markets 09:30:00 2024-07-10 am EDT			5-day change	1st Jan Change
0.23 ^CAD	-2.13%		-2.13%	+9.52%

Jun. 14	Helix BioPharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2024	CI
May. 31	Helix BioPharma Corp. announced that it has received CAD 2.35 million in funding	CI

Helix Biopharma : Corp. Appoints Jack Kay As Chairman Of The Board And Professor Kazimierz Roszkowski- SLliz As European Medical Director

January 09, 2012 at 04:43 pm EST

MarketScreener.com By

3-305 Industrial Parkway South
Aurora, Ontario, Canada, L4G 6X7
Phone: (905) 841-2300
Fax: (905) 841-2244
Web: www.helixbiopharma.com

January 9, 2012 NEWS RELEASE HELIX BIOPHARMA CORP. APPOINTS JACK KAY AS CHAIRMAN OF THE BOARD AND PROFESSOR KAZIMIERZ ROSZKOWSKI-

© Publicnow - 2012

Latest news about Helix BioPharma Corp.

Helix BioPharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2024	Jun. 14	CI
Helix BioPharma Corp. announced that it has received CAD 2.35 million in funding	May. 30	CI
Helix BioPharma Corp. Reports Earnings Results for the Second Quarter and Six Months Ended January 31, 2024	May. 13	CI
Helix BioPharma Corp. announced that it has received CAD 1.915 million in funding	Apr. 07	CI
Helix BioPharma Corp. announced that it expects to receive CAD 1.915 million in funding	Mar. 27	CI
North American Morning Briefing : Markets Steady -2-	Mar. 26	DJ
Helix BioPharma Corp. Appoints Praveen Varshney as Corporate Secretary	Feb. 13	CI
Helix BioPharma Corp. Appoints Praveen Varshney as Chief Financial Officer	Feb. 13	CI
North American Morning Briefing : S&P 500 Eyes Record High as Rate Cut Hopes Underpin Sentiment	Dec. 19	DJ
Helix BioPharma Corp. Reports Earnings Results for the First Quarter Ended October 31, 2023	Dec. 14	CI
North American Morning Briefing : Traders Eye -2-	Dec. 12	DJ
Helix BioPharma Corp. Reports Earnings Results for the Full Year Ended July 31, 2023	23-10-27	CI
Helix BioPharma Corp. announced that it has received CAD 2.998 million in funding	23-10-26	CI
Helix BioPharma Corp. to Present New Preclinical Data on L-DOS47 in Combination with PD1 Checkpoint Inhibitor at the 2023 AACR- NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics	23-10-10	CI
Helix Biopharma Corp. Announces Board Changes	23-08-22	CI
Helix BioPharma Corp. Announces Executive Changes	23-08-22	CI
Helix BioPharma Corp. announced that it expects to receive CAD 2.998 million in funding	23-08-14	CI
Helix BioPharma Corp. Reports Earnings Results for the Third Quarter and Nine Months Ended April 30, 2023	23-06-14	CI
North American Morning Briefing : Futures Rise -2-	22-12-21	DJ
Helix BioPharma Corp. Reports Earnings Results for the First Quarter Ended October 31, 2022	22-12-14	CI
North American Morning Briefing : Investors Wary -2-	22-12-14	DJ
Helix BioPharma Corp. Announces Board Changes	22-12-08	CI
Helix BioPharma Corp. Announces CEO Changes	22-12-08	CI
Helix BioPharma Corp. Reports Earnings Results for the Full Year Ended July 31, 2022	22-10-31	CI
Helix BioPharma Corp. announced that it has received CAD 4.62902 million in funding	22-10-30	CI

Company Profile
Helix BioPharma Corp. is a Canada-based clinical-stage biopharmaceutical company. The Company is engaged in developing therapies in the field of immuno-oncology, based on its proprietary technological platform DOS47. DOS47 is an oncology platform technology that offers a debilitation and destruction of cancer cells. DOS47 is designed to stimulate an increase in the Potential of Hydrogen (pH) of the microenvironment surrounding the cancerous cells, effectively reversing the acidic extra cellular conditions that are believed to act to defend the tumor. L-DOS47 is an antibody protein conjugate where the urease component enzymatically converts naturally occurring urea to ammonia. The L-DOS47 drug molecule includes a specialized camelid-derived single domain antibody and is under clinical study for the treatment of non-small cell lung cancer and pancreatic cancer. V-DOS47 targets the vascular endothelial growth factor two receptor (VEGFR2).
Sector
Biotechnology & Medical Research
Calendar
2024-10-24 - Q4 2024 Earnings Release (Projected)
More about the company

Income Statement Evolution
More financial data

Annual profits - Rate of surprise
Company calendar

Sector Other Biotechnology & Medical Research
1st Jan change Capi.
HELIX BIOPHARMA CORP.
+9.52% 41.38M
MODERNA, INC.
+23.50% 47.07B
LONZA GROUP AG
+47.70% 42.06B
IQVIA HOLDINGS INC.
-5.16% 39.98B
ALNYLAM PHARMACEUTICALS, INC.
+36.37% 33.02B
CELLTRION, INC.
-7.79% 27.9B
ICON PUBLIC LIMITED COMPANY
+18.06% 27.63B
UNITED THERAPEUTICS CORPORATION
+47.29% 14.37B
MEDPACE HOLDINGS, INC.
+41.91% 13.45B
BIO-TECHNE CORPORATION
-1.02% 12.03B
Other Biotechnology & Medical Research